Clinical Trials

We are currently enrolling patients in a multi-site Phase I study of the MagSense® HER2 imaging agent.

Learn more about the clinical study

Simple, bio-safefunctional imaging

MagSense® technology is the first imaging technology to use targeted magnetic nanoparticles to tag and detect cancers. The tiny bio-safe particles act as a magnetic beacon detectable when they attach to cancer cells.

Learn more about MagSense®

Designated by the FDA as a "breakthrough device"

Designated by the US FDA as a “Breakthrough Device”,
MagSense® technology will help transform cancer care.

Learn more

How does MagSense® imaging technology work?

Based on the principles of superparamagnetic relaxometry, the tiny magnetic nanoparticles produce a detectable magnetic signature.

Learn more

How is MagSense® better than other imaging methods?

MagSense® technology does not use ionizing radiation, radioactive tracers, or strong magnetic fields.

Learn more

How will MagSense® change cancer detection?

Most cancers are asymptomatic, growing unnoticed and undetected until the tumor has grown large enough to cause identifiable symptoms.

Learn more